
Shares of healthcare conglomerate Johnson & Johnson JNJ.N fall 1.9% to $214.13
On Tuesday, a court-appointed special master recommended that expert testimony linking the company's talc products to ovarian cancer be allowed in court
J&J has been fighting claims over its talc products in both federal and state court for years, but it has maintained that its products are safe and do not cause cancer
"The talc litigation concerns may be driving the stock down slightly in pre-market trading," RBC Capital Markets analysts wrote in a note
Co forecasts 2026 adj. profit in the range of $11.43 and $11.63 per share, above analysts' estimate of $11.45 per share, according to data compiled by LSEG
JNJ posts Q4 adj. profit of $2.46 per share, compared with analysts' estimate of $2.44 per share
Reports Q4 revenue of $24.56 billion, beating estimates of $24.16 billion
JNJ stock climbed 43.1% in 2025